Sample sizes for clinical trials using sputum eosinophils as a primary outcome

European Respiratory Journal

Volumn 42, Issue 4, 2013, Pages 1003-1011

  Dasgupta, Angira ^a   Zhang, Shiyuan ^a,b   Thabane, Lehana ^a,b   Nair, Parameswaran ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MEPOLIZUMAB; PLACEBO;

ARTICLE; ASTHMA; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; EFFECT SIZE; EOSINOPHIL; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SPUTUM; SYSTEMATIC REVIEW;

ALLERGENS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DATA INTERPRETATION, STATISTICAL; EOSINOPHILS; HUMANS; INFLAMMATION; INTERVENTION STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; SPUTUM; TREATMENT OUTCOME;

EID: 84886573031     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00075712     Document Type: Article

References (33)

1. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154: 308-317.
2. Nair PK, Hargreave FE. Airway diseases, inflammometry and individualized therapy. In: Polosa R, Holgate ST, eds. Therapeutic Strategies. Asthma: Current Treatments. Oxford, Clinical Publishing, 2007; pp. 155-164.
3. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
4. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
5. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213-2214.
6. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155: 1501-1508.
7. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
8. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001; 1: 6.
9. Dente FL, Bacci E, Bartoli ML, et al. Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma. Ann Allergy Asthma Immunol 2010; 104: 464-470.
10. Zhong BL. How to calculate sample size in randomized controlled trial? J Thorac Dis 2009; 1: 51-54.
11. Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000; 161: 475-478.
12. Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 2007; 60: 1234-1238.
13. Jayaram L, Pizzichini E, Lemière C, et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax 2005; 60: 100-105.
14. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
15. Kanniess F, Richter K, Böhme S, et al. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002; 20: 853-858.
16. Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121: 732-738.
17. Urata Y, Yoshida S, Irie Y, et al. Treatment of asthma patients with herbal medicine TJ-96: a randomized controlled trial. Respir Med 2002; 96: 469-474.
18. Yoshida M, Aizawa H, Inoue H, et al. Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients. J Asthma 2002; 39: 545-552.
19. Grootendorst DC, Gauw SA, Benschop N, et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 2003; 16: 341-347.
20. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-593.
21. Kobayashi M, Nasuhara Y, Betsuyaku T, et al. Effect of low-dose theophylline on airway inflammation in COPD. Respirology 2004; 9: 249-254.
22. ten Brinke A, Zwinderman AH, Sterk PJ, et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170: 601-605.
23. Jayaram L, Duong M, Pizzichini MM, et al. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. Eur Respir J 2005; 25: 41-46.
24. Green RH, Brightling CE, McKenna S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 2006; 27: 1144-1151.
25. Hauber H, Taha R, Bergeron C, et al. Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients. Can Respir J 2006; 13: 73-78.
26. Haverkamp HC, Dempsey JA, Pegelow DF, et al. Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects. J Allergy Clin Immunol 2007; 120: 39-47.
27. Pavord I, Woodcock A, Parker D, et al. Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma. Respir Res 2007; 8: 67.
28. Chen YH, Yao WZ, Ding YL, et al. Effect of theophylline on endogenous hydrogen sulfide production in patients with COPD. Pulm Pharmacol Ther 2008; 21: 40-46.
29. Duong M, Subbarao P, Adelroth E, et al. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. Chest 2008; 133: 404-411.
30. Hoshino M, Handa H, Miyazawa T. Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. Allergol Int 2009; 58: 357-363.
31. Pavord ID, Jeffery PK, Qiu Y, et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol 2009; 123: 1083-1089.
32. Kelly MM, Leigh R, Jayaram L, et al. Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J Allergy Clin Immunol 2006; 117: 989-994.
33. Turner MO, Johnston PR, Pizzichini E, et al. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J 1998; 5: 261-268.